Navigation Links
Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
Date:8/31/2009

NASHVILLE, Tenn., Aug. 31 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the UBS Global Life Sciences Conference in New York at 11:00 a.m. Eastern Time on Monday, September 21, 2009. Mr. Kazimi will provide an update on the Company and its Caldolor product, which Cumberland is preparing to launch following its recent approval by the Food and Drug Administration.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast, a replay will be available and archived for 30 days.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company recently completed an initial public offering of its common stock.

For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

Statements contained in this press release that are not historical facts are "forwardlooking" statements within the meaning of the federal securities laws. Forward-looking statements are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. Additional information regarding such risks can be found in the Company's Registration Statement declared effective by the SEC on August 10, 2009.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Drs. Justin ... Awareness Week by teaching their patients about the key role this treatment plays in ... from an experienced endodontist. To better serve those who need a root canal in ...
(Date:3/27/2017)... Scottsdale, Arizona (PRWEB) , ... March 27, 2017 , ... ... in the top 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo ... New York on April 8. , Project Entrepreneur’s second annual venture competition ignites ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... ... 27, 2017 , ... The Association of Healthcare and Value ... their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide the ... value analysis professionals have a ‘seat at the table’ with clinical committees when ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... IRVINE, Calif. , March 24, 2017 ... ,the epigenetics company, and Hamilton Robotics, Inc., ... workstations, announced an ongoing collaboration that teams ... products and RNA and DNA extraction products ... has already created optimized methods for microbiomics ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... offering. ... the worldwide markets for Dental Implants in US$ Million. The report provides ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology: